

# FINANCIAL REPORT 2025

---

1300 37 45 37

[www.epilepsy.org.au](http://www.epilepsy.org.au)

[epilepsy@epilepsy.org.au](mailto:epilepsy@epilepsy.org.au)



**Epilepsy  
Action  
Australia**



**EPILEPSY ACTION AUSTRALIA**

**ABN 61 000 533 791**

**FINANCIAL REPORT - 30 JUNE 2025**

**CONTENTS**

Directors' Report	1
Auditor's Independence Declaration	4
Statement of Financial Position	5
Statement of Profit or Loss and Other Comprehensive Income	6
Statement of Changes in Funds	7
Statement of Cash Flows	8
Notes to the Financial Statements	9
Directors' Declaration	19
Directors' Declaration under the <i>Charitable Fundraising Act</i>	20
Independent Auditor's Report	21

**EPILEPSY ACTION AUSTRALIA**  
**ABN 61 000 533 791**

**FINANCIAL REPORT - 30 JUNE 2025**

**DIRECTORS' REPORT**

The names of and other information on the Directors in office during or since the end of the year are as follows. The Directors were in office for this entire period unless otherwise stated.

<b>DIRECTOR</b>	<b>DATE APPOINTED</b>	<b>SPECIAL EAA RESPONSIBILITIES</b>	<b>HELD OFFICE UNTIL</b>
Erica Siu-Gregan	20 May 2019	Chair of the Board <i>(effective from 30 October 2023)</i>	
Lisa Dive PH.D Philosophy	13 November 2015	Member of the Governance Committee	
Jeff Fryer	30 November 2023	Member of the Finance, Audit, Compliance and Risk Committee	
Carol Ireland Dip Reh. Couns., FAIM, MFIA	29 June 2009	Managing Director Chief Executive Officer Company Secretary Member of the Governance Committee	
Roy Marrett B.Com FCCA	25 July 2016	Member of the Finance, Audit, Compliance and Risk Committee	
Jayne Meyer Tucker	30 October 2023		
David Oudshoorn	30 October 2023		
Erin Oudshoorn	30 October 2023		
Alan Shields	30 October 2023		

**PRINCIPAL ACTIVITY**

The principal activity of the company continues to be being a registered charity providing client support services, education and fundraising for Epilepsy. There were no significant changes in the nature of the principal activities during the year.

**OPERATING RESULT**

The net result of the company for the financial year after providing for income tax was a deficit of \$306,815 (2024: surplus \$1,287,126). The company is a not-for-profit entity and is exempt from the payment of income tax.

**VISION**

Inclusion, equitable access, and self-determination for people living with epilepsy.

**MISSION**

Epilepsy Action Australia ('EAA') drives positive change empowered by the collective voice of people living with epilepsy.

**EPILEPSY ACTION AUSTRALIA**  
**ABN 61 000 533 791**

**FINANCIAL REPORT - 30 JUNE 2025**

**DIRECTORS' REPORT**

**KEY STRATEGIES**

There are four strategic outcomes that will enable achievement of the EAA vision and mission, and guide service delivery and business operations. The four outcomes agreed by the Board and management team are:

1. Elevating the understanding of epilepsy and its impacts in the broader community to enable equitable access (Advocacy)
2. Enhancing self-management capabilities by improving access to epilepsy information, services and support (Direct Services)
3. Increasing the knowledge and skills of those supporting people with epilepsy (Knowledge and Skills)
4. Investing in research to optimise future outcomes for people living with epilepsy (Research)

**KEY PERFORMANCE MEASURES**

The company's performance over 5 years will be measured against the following program measures:

**AWARENESS**

- Media and social media hits, website hits
- Ambassadors, volunteers etc
- Consumers/referrals/interactions
- HCPs engaged

**KNOWLEDGE AND SKILLS**

- Sales
- Uptake of courses
- Participant completions and satisfaction

**CONSUMER SERVICES**

- Consumer satisfaction
- Service outcomes
- Referrals

**RESEARCH**

- Research projects and outcomes
- Publications
- Increase in and strengthened partnerships
- Increased consumer involvement in research
- Attracting research funding

**SUCCESS IN REVENUE GENERATION**

- Donor acquisition and retention measures
- Campaign and overall budget results
- Conversions (upgrades, bequests etc)
- New leads and introductions

**LIMITATION OF MEMBERS' LIABILITY**

The company is registered under the *Australian Charities and Not-for-profits Commission Act 2012* as a company limited by guarantee. If the company is wound up, its Constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the company. At 30 June 2025 the number of members was 46 and their collective liability was \$460.

**EPILEPSY ACTION AUSTRALIA**  
**ABN 61 000 533 791**

**FINANCIAL REPORT - 30 JUNE 2025**

**DIRECTORS' REPORT**

**MEETINGS OF DIRECTORS**

The number of meetings each Director was eligible to attend and actually attended during the financial year is summarised as follows:

	<b>Eligible</b>	<b>Attended</b>
Erica Siu-Gregan	6	6
Lisa Dive	6	5
Jeff Fryer	6	5
Carol Ireland	6	6
Roy Marrett	6	4
Jayne Meyer Trucker	6	6
David Oudshoorn	6	3
Erin Oudshoorn	6	5
Alan Shields	6	6

**INDEPENDENCE DECLARATION**

The auditors' independence declaration for the year ended 30 June 2025 has been received and can be found on the following page.

Signed in accordance with a resolution of the Board of Directors:



Erica Siu-Gregan  
Chair

Sydney, 25 August 2025

**EPILEPSY ACTION AUSTRALIA**

**ABN 61 000 533 791**

**FINANCIAL REPORT - 30 JUNE 2025**

**AUDITOR'S INDEPENDENCE DECLARATION UNDER s60-40**  
**OF THE AUSTRALIAN CHARITIES AND NOT-FOR-PROFITS COMMISSION ACT 2012**  
**TO THE DIRECTORS OF EPILEPSY ACTION AUSTRALIA**

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2025 there has been:

- (a) no contraventions of the auditor independence requirements as set out in the *Australian Charities and Not-for-profits Commission Act 2012* in relation to the audit; and
- (b) no contraventions of any applicable code of professional conduct in relation to the audit.



**StewartBrown**  
Chartered Accountants



**David Gallery**  
Partner

25 August 2025

**EPILEPSY ACTION AUSTRALIA****ABN 61 000 533 791****STATEMENT OF FINANCIAL POSITION****AS AT 30 JUNE 2025**

	Note	2025 \$	2024 \$
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents	6	2,247,917	2,459,798
Trade and other receivables	7	80,378	132,149
Other assets	8	74,810	75,596
<i>Total current assets</i>		<u>2,403,105</u>	<u>2,667,543</u>
<b>Non-current assets</b>			
Property, plant and equipment	9	13,932	3,584
Intangible assets	10	-	5,386
Right-of-use assets	11	138,832	290,296
<i>Total non-current assets</i>		<u>152,764</u>	<u>299,266</u>
<b>TOTAL ASSETS</b>		<u>2,555,869</u>	<u>2,966,809</u>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Trade and other payables	12	308,395	249,823
Lease liabilities	13	163,608	158,042
Employee benefits	14	233,581	251,883
<i>Total current liabilities</i>		<u>705,584</u>	<u>659,748</u>
<b>Non-current liabilities</b>			
Lease liabilities	13	-	163,608
Employee benefits	14	42,556	28,909
<i>Total non-current liabilities</i>		<u>42,556</u>	<u>192,517</u>
<b>TOTAL LIABILITIES</b>		<u>748,140</u>	<u>852,265</u>
<b>NET ASSETS</b>		<u><u>1,807,729</u></u>	<u><u>2,114,544</u></u>
<b>FUNDS</b>			
Accumulated funds		<u>1,807,729</u>	<u>2,114,544</u>
<b>TOTAL FUNDS</b>		<u><u>1,807,729</u></u>	<u><u>2,114,544</u></u>

The accompanying notes form part of these financial statements

**EPILEPSY ACTION AUSTRALIA****STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**  
**FOR THE YEAR ENDED 30 JUNE 2025**

	Note	2025 \$	2024 \$
<b>Revenue</b>			
Operating revenue	4	3,204,018	4,894,041
		<u>3,204,018</u>	<u>4,894,041</u>
<b>Expenses</b>			
Administration expenses		(426,606)	(397,145)
Depreciation and amortisation	5	(163,996)	(162,711)
Employee benefits expense		(2,196,245)	(2,178,447)
Events expenses		(80,233)	(113,250)
Finance costs	5	(7,488)	(12,148)
Marketing expenses		(427,973)	(468,216)
Travel expenses		(13,979)	(43,505)
Research expenses		(100,587)	(100,000)
Training expenses		(93,726)	(131,493)
		<u>(3,510,833)</u>	<u>(3,606,915)</u>
<b>Surplus (deficit) before income tax</b>		(306,815)	1,287,126
Income tax expense		-	-
<b>Surplus (deficit) for the year</b>		(306,815)	1,287,126
<b>Other comprehensive income</b>		-	-
<b>Total comprehensive income (loss) for the year</b>		<u><u>(306,815)</u></u>	<u><u>1,287,126</u></u>

The accompanying notes form part of these financial statements

**EPILEPSY ACTION AUSTRALIA****STATEMENT OF CHANGES IN FUNDS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

	<b>Accumulated Funds</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>
<b>Balance at 1 July 2023</b>	827,418	827,418
<b>Comprehensive income</b>		
Surplus for the year	1,287,126	1,287,126
Other comprehensive income	-	-
<b>Total comprehensive income for the year</b>	<u>1,287,126</u>	<u>1,287,126</u>
<b>Balance at 30 June 2024</b>	<u><b>2,114,544</b></u>	<u><b>2,114,544</b></u>
<b>Balance at 1 July 2024</b>	2,114,544	2,114,544
<b>Comprehensive income</b>		
Surplus (deficit) for the year	(306,815)	(306,815)
Other comprehensive income	-	-
<b>Total comprehensive income (loss) for the year</b>	<u>(306,815)</u>	<u>(306,815)</u>
<b>Balance at 30 June 2025</b>	<u><b>1,807,729</b></u>	<u><b>1,807,729</b></u>

**EPILEPSY ACTION AUSTRALIA****STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

	Note	2025 \$	2024 \$
<b>Cash flows from operating activities</b>			
Receipts from customers and government		1,596,390	1,553,975
Payments to suppliers and employees		(3,504,888)	(3,457,818)
Donations, legacies and fundraising receipts		1,798,871	3,317,501
Interest received		80,770	26,700
Interest paid - leases		(7,488)	(12,148)
<i>Net cash flows from operating activities</i>		<u>(36,345)</u>	<u>1,428,210</u>
<b>Cash flows from investing activities</b>			
Purchase of property, plant and equipment		(17,494)	(4,103)
<i>Net cash flows from investing activities</i>		<u>(17,494)</u>	<u>(4,103)</u>
<b>Cash flows from financing activities</b>			
Repayment of lease liabilities		(158,042)	(152,925)
<i>Net cash flows from financing activities</i>		<u>(158,042)</u>	<u>(152,925)</u>
Net increase (decrease) in cash and cash equivalents		(211,881)	1,271,182
Cash and cash equivalents at the beginning of the financial year		<u>2,459,798</u>	<u>1,188,616</u>
Cash and cash equivalents at the end of the financial year	6	<u><u>2,247,917</u></u>	<u><u>2,459,798</u></u>

The accompanying notes form part of these financial statements

**EPILEPSY ACTION AUSTRALIA****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025****Note 1 - Corporate information**

The financial report includes the financial statements and notes of Epilepsy Action Australia ('the company'). Epilepsy Action Australia is registered as a company limited by guarantee and not having a share capital under the provisions of the *Australian Charities and Not-for-profits Commission Act 2012*.

The company provides services to all those affected by epilepsy, including self-management resources and tools, tailored plans, emotional support and access to a network of specialist providers.

The registered address and principal place of business of the company is:

Suite 7.02, Level 7  
18-20 Orion Road  
Lane Cove West NSW 2066

The financial statements were approved by the Board of Directors on 25 August 2025.

**Note 2 - Basis of preparation*****Statement of compliance***

These general purpose financial statements have been prepared in compliance with the requirements of the *Australian Charities and Not-for-profits Commission Act 2012* and *Australian Accounting Standards - Simplified Disclosures*. The company is a not-for-profit entity for the purposes of preparing these financial statements.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in financial statements containing relevant and reliable information about transactions, events and conditions.

***Basis of measurement***

The financial statements, except for the cash flow information, have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

***Comparatives***

Where required by Accounting Standards or to achieve consistency in financial statements presentation, the prior year financial comparatives have been adjusted to conform with current year disclosures and allow comparison with current financial year disclosures.

***Critical accounting estimates and judgements***

The Directors evaluate estimates and judgements incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company.

**Key estimates*****Impairment - general***

The Directors assess impairment at the end of each reporting period by evaluation of conditions and events specific to the company that may be indicative of impairment triggers. Recoverable amounts of relevant assets are reassessed using value-in-use calculations which incorporate various key assumptions.

***Estimation of useful lives of assets***

The estimation of the useful lives of assets has been based on historical experience as well as manufacturers' warranties (for plant and equipment) and turnover policies (for motor vehicles). In addition, the condition of the assets is assessed at least once per year and considered against the remaining useful life. Adjustments to useful lives are made when considered necessary.

**EPILEPSY ACTION AUSTRALIA****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025****Note 2 - Basis of preparation (continued)*****New and revised standards that are effective for these financial statements***

Several amendments and clarifications to Australian Accounting Standards and interpretations are mandatory for the 30 June 2025 reporting period. These include:

- *AASB 2020-1, AASB 2022-6 and AASB 2023-3: Amendments to AASB 101 – Classification of Liabilities as Current or Non-current*
- *AASB 2023-1: Amendments to AASB 7 and 107 – Supplier Finance Arrangements*
- *AASB 2024-1: Amendments to AASB 1060 – Supplier Finance Arrangements: Tier 2 Disclosures*

The application of these amendments and clarifications have not had a material impact on the carrying values of the company's asset, liability or equity balances; nor a material impact on the disclosures in the financial report nor the recognition and measurement of the company's revenue or expenses.

***New standards and interpretations not yet adopted***

Certain new accounting standards, amendments and interpretations have been published that are not mandatory for 30 June 2025 reporting periods and have not been early adopted by the company. These include:

- *AASB 18 – Presentation and Disclosure in Financial Statements* (applicable for the year ending 30 June 2028)
- *AASB S1 – General Requirements for Disclosure of Sustainability-related Financial Information* (applicable for the year ending 30 June 2026, depending on criteria qualification outcomes)
- *AASB S2 – Climate-related Disclosures* (applicable for the year ending 30 June 2026, depending on criteria qualification outcomes)

It is not expected that *AASB 18*, *AASB S1* or *AASB S2* will have a material impact on the company in future reporting periods. *AASB S1* and *AASB S2* will only have mandatory application to entities required to report under Chapter 2M of the *Corporations Act 2001* for annual reporting periods commencing on or after 1 July 2025. The company is currently assessing whether there will be any material change to disclosures in financial reporting in future years as a consequence of sustainability reporting requirements. As at the date of this financial report *AASB S1* and *AASB S2* do not have mandatory application to the company as the company prepares its financial report under the *Australian Charities and Not-for-profits Commission Act 2012* financial reporting framework.

***Going concern***

The financial statements are prepared on a going concern basis. The Directors or the company have performed a detailed budget analysis for the forthcoming twelve months from adoption of these financial statements and developed plans to manage the business of the company to the expected revenues. The Directors also have initiatives and plans in place to improve the profitability and cash flow of the company in the short term.

On the basis that the 2025-26 forecast results can be achieved, including the receipt of ongoing support from the company's donors, benefactors, sponsors, other givers and government, the Directors believe that the company is a going concern and that the assets and liabilities will be realised at the values presented in the financial statements.

**Note 3 - Accounting policies**

The material accounting policies adopted in the preparation of the financial report are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

***Goods and services tax (GST)***

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

**EPILEPSY ACTION AUSTRALIA****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025****Note 3 - Accounting policies (continued)*****Goods and services tax (GST)(continued)***

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to, the ATO are presented as operating cash flows included in receipts from customers or payments to suppliers.

***Income tax***

Epilepsy Action Australia is a not-for-profit exempt institution from income tax under Division 50 of the *Income Tax Assessment Act 1997*. Epilepsy Action Australia has deductible gift recipient (DGR) status.

***Revenue recognition***

Amounts disclosed as revenue are net of returns, trade allowances and duties and taxes including goods and services tax (GST). Revenue is recognised for the major business activities as follows:

***Government grants***

Government grants are recognised at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to expense items are recognised as income over the periods necessary to match the grant to the costs they are compensating. Grants relating to assets are credited to deferred income at fair value and are credited to income over the expected useful life of the asset on a straight-line basis.

***Interest revenue***

Interest revenue is recognised on a proportional basis taking into account the interest rates applicable to the financial assets.

***Donations***

Income arising from the contribution of an asset (including cash) is recognised when the following conditions have been satisfied:

- a) the company obtains control of the contribution or the right to receive the contribution;
- b) it is probable that the economic benefits comprising the contribution will flow to the company; and
- c) the amount of the contribution can be measured reliably at the fair value of the consideration received.

***Cash and cash equivalents***

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of twelve months or less that are readily convertible to known amounts of cash, and which are subject to an insignificant risk of changes in value and bank overdrafts.

***Trade receivables***

For all sources of recurrent income, trade receivables are recognised initially at fair value and subsequently measured at amortised cost, less provision for doubtful debts. Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectible are written off. A provision for impairment is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of receivables.

The amount of the provision is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the effective interest rate. The amount of the provision is recognised in the statement of profit or loss and other comprehensive income.

**EPILEPSY ACTION AUSTRALIA****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025****Note 3 - Accounting policies (continued)*****Property, plant and equipment*****Recognition and measurement**

Each class of property, plant and equipment is carried at cost less, where applicable, any accumulated depreciation and impairment losses.

**Depreciation**

The depreciable amount of all property, plant and equipment and capital works in progress, is depreciated on a straight line basis over the asset's useful life to the company commencing from the time the asset is held ready for use.

The depreciation rates used for each class of depreciable assets are:

IT equipment	33%
Furniture and equipment	20% - 33%
Motor vehicles	20%

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

***Leases***

The company leases business premises on an arm's length basis from a third-party lessor. A lease is a contract, or part of a contract, that conveys the right to use an asset for a period of time in exchange for consideration.

At inception of a contract, it is assessed to determine whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If the terms and conditions of a contract are changed, it is reassessed to once again determine if the contract is still, or now contains, a lease.

***Right-of-use assets***

At inception, a right-of-use asset and lease liability is recognised. Right-of-use assets are included in the statement of financial position within a classification relevant to the underlying asset.

Right-of-use assets are initially measured at cost, comprising of the following:

- The amount of the initial measurement of the lease liability
- Any lease payments made at or before the commencement date, less any lease incentives received
- Any initial direct costs incurred
- An estimate of costs to be incurred in dismantling and removing the underlying asset, restoring the site on which it is located or restoring the underlying asset to the condition required by the terms and conditions of the lease, unless those costs are incurred either at the commencement date or as a consequence of having used the underlying asset during a particular period

Subsequently, right-of-use assets are measured using a cost model. The right-of-use asset is depreciated to the earlier of the useful life of the asset or the lease term using the straight-line method and is recognised in the statement of profit or loss and other comprehensive income in "Depreciation and amortisation".

***Lease liability***

At the commencement date of the lease, the lease liability is initially recognised for the present value of non-cancellable lease payments discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the company's incremental borrowing rate.

**EPILEPSY ACTION AUSTRALIA****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025****Note 3 - Accounting policies (continued)*****Intangible assets***

Intangible assets acquired separately are capitalised at fair value as at the date of acquisition. Following initial recognition, the cost model is applied to the class of intangible assets. The useful lives of intangible assets are assessed to be either finite or indefinite. Where amortisation is charged on intangible assets with finite lives, this expense is taken to the statement of comprehensive income through the "depreciation and amortisation" line item.

***Impairment of assets***

Assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment. Assets that are subject to amortisation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash generating units). Impairment losses are reversed when there is an indication that the impairment loss may no longer exist and there has been a change in the estimate used to determine the recoverable amount.

***Trade and other payables***

Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the company during the reporting period, which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability. The carrying amount of trade and other payables is deemed to reflect fair value.

***Income received in advance***

Income, other than government contract income, that is received before the service to which the payment relates has been provided is recorded as a liability until such time as the service has been provided, at which time it is recognised in the statement of comprehensive income.

***Unexpended grants***

The company receives grant monies to fund projects either for contracted periods of time or for specific projects irrespective of the period of time required to complete these projects. It is the policy of the company to treat grant monies as revenue in advance in the statement of financial position where the company is contractually obliged to provide the services in a subsequent financial period to when the grant is received or in the case of specific project grants where the project has not been completed.

***Employee benefits***

Provision is made for the company's liability for employee benefits arising from services rendered by employees to the end of the reporting period. Employee benefits that are expected to be settled within one year have been measured at the amounts expected to be paid when the liability is settled. Employee benefits payable later than one year have been measured at the present value of the estimated future cash outflows to be made for those benefits. In determining the liability, consideration is given to employee wage increases and the probability that the employee may not satisfy vesting requirements. Those cash outflows are discounted using market yields on high quality corporate bonds with terms to maturity that match the expected timing of cash flows.

**EPILEPSY ACTION AUSTRALIA****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

	2025	2024
	\$	\$
<b><u>Note 4 - Revenue and other income</u></b>		
<b>Operating revenue</b>		
Fundraising and event income	861,169	834,856
Bequests	1,650	1,425,386
Donations	936,052	1,057,259
Government grants (refer Note 17)	449,043	608,861
Interest income	80,770	26,700
Membership	2,523	3,204
Training and education income	808,483	850,038
Sponsorship	33,500	11,500
Other operating revenue	30,828	76,237
<i>Total operating revenue</i>	<u>3,204,018</u>	<u>4,894,041</u>
<b><u>Note 5 - Expenses</u></b>		
Depreciation and amortisation		
Property, plant and equipment	7,146	5,847
Right-of-use assets	151,464	151,464
Software and website	5,386	5,400
<i>Total depreciation and amortisation</i>	<u>163,996</u>	<u>162,711</u>
Finance costs - lease liability	7,488	12,138
Finance costs - other	-	10
<b><u>Note 6 - Cash and cash equivalents</u></b>		
Cash at bank and on hand	545,808	1,982,873
Deposits at call	1,702,109	476,925
<i>Total cash and cash equivalents</i>	<u>2,247,917</u>	<u>2,459,798</u>
<b><u>Note 7 - Trade and other receivables</u></b>		
<u>Current</u>		
Trade receivables	17,688	108,372
Accrued income	62,690	1,800
Other receivables	-	21,977
<i>Total current trade and other receivables</i>	<u>80,378</u>	<u>132,149</u>
<b><u>Note 8 - Other assets</u></b>		
<u>Current</u>		
Prepayments	74,810	75,596
<i>Total other assets</i>	<u>74,810</u>	<u>75,596</u>

**EPILEPSY ACTION AUSTRALIA****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025****Note 9 - Property, plant and equipment**

	IT Equipment \$	Furniture and Equipment \$	Total \$
<b>At 30 June 2024</b>			
Cost	70,742	54,753	125,495
Accumulated depreciation	(67,158)	(54,753)	(121,911)
<i>Net carrying amount</i>	<u>3,584</u>	<u>-</u>	<u>3,584</u>
<b>Movements in carrying amounts</b>			
Opening net carrying amount	3,584	-	3,584
Additions	17,494	-	17,494
Depreciation charge for the year	(7,146)	-	(7,146)
Closing net carrying amount	<u>13,932</u>	<u>-</u>	<u>13,932</u>
<b>At 30 June 2025</b>			
Cost	88,215	54,753	142,968
Accumulated depreciation	(74,283)	(54,753)	(129,036)
<i>Net carrying amount</i>	<u>13,932</u>	<u>-</u>	<u>13,932</u>

	2025 \$	2024 \$
<b>Note 10 - Intangible assets</b>		
<b>Software</b>		
Cost	746,732	746,732
Accumulated amortisation	(746,732)	(741,346)
<i>Total intangible assets</i>	<u>-</u>	<u>5,386</u>
<b>Movements in carrying amounts</b>		
Opening net carrying amount	5,386	10,786
Amortisation charge for the year	(5,386)	(5,400)
Closing net carrying amount	<u>-</u>	<u>5,386</u>

**Note 11 - Right-of-use assets**

Leased offices - at cost	757,307	757,307
Accumulated depreciation	(618,475)	(467,011)
<i>Total right-of-use assets</i>	<u>138,832</u>	<u>290,296</u>
<b>Movements in carrying amounts</b>		
Opening net carrying amount	290,296	441,760
Depreciation charge for the year	(151,464)	(151,464)
Closing net carrying amount	<u>138,832</u>	<u>290,296</u>

**Leasing information**

Epilepsy Action Australia leases its principal place of business on an arm's length basis from a third party lessor. The lease term commenced in June 2021 and concludes in June 2026. A lease liability has been recognised in the financial statements (refer Note 13) for the discounted value of the lease payments to be made by the company up to and including June 2026.

**EPILEPSY ACTION AUSTRALIA****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

	2025	2024
	\$	\$
<b><u>Note 12 - Trade and other payables</u></b>		
<u>Current</u>		
Trade payables	47,525	54,266
Income in advance	167,027	72,789
Other payables	93,843	122,768
<i>Total current trade and other payables</i>	<u>308,395</u>	<u>249,823</u>
<b><u>Note 13 - Lease liabilities</u></b>		
<u>Current</u>		
Lease liabilities	163,608	158,042
<i>Total current lease liabilities</i>	<u>163,608</u>	<u>158,042</u>
<u>Non-current</u>		
Lease liabilities	-	163,608
<i>Total non-current lease liabilities</i>	<u>-</u>	<u>163,608</u>
<b><i>Movements in carrying amounts</i></b>		
Opening net carrying amount	321,650	474,575
Repayments	(165,530)	(165,063)
Interest	7,488	12,138
Closing net carrying amount	<u>163,608</u>	<u>321,650</u>
<b><u>Note 14 - Employee benefits</u></b>		
<u>Current</u>		
Annual leave	126,908	137,976
Long service leave	106,673	113,907
<i>Total current employee benefits</i>	<u>233,581</u>	<u>251,883</u>
<u>Non-current</u>		
Long service leave	42,556	28,909
<i>Total non-current employee benefits</i>	<u>42,556</u>	<u>28,909</u>
<b><i>Movements in carrying amount</i></b>		
Opening net carrying amount	280,792	252,424
Additional provision recognised	193,188	144,282
Provision utilised during the year	(197,843)	(115,914)
Closing net carrying amount	<u>276,137</u>	<u>280,792</u>
<b><u>Note 15 - Key management personnel</u></b>		
<b><i>Remuneration of key management personnel</i></b>		
The aggregate amount of compensation paid to key personnel during the year was:	<u>771,573</u>	<u>557,484</u>

***Changes in KMP Composition***

During the 2025 financial year, the Fundraising Manager was assessed as meeting the definition of KMP under *AASB 124 Related Party Disclosures*, reflecting the strategic importance of fundraising to growth. This role was not included in the key management personnel remuneration disclosure in the prior year.

**EPILEPSY ACTION AUSTRALIA****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

	2025	2024
	\$	\$
<b><u>Note 16 - Auditor's remuneration</u></b>		
Fees paid to StewartBrown, Chartered Accountants:		
Audit of the financial report	30,500	29,000
Preparation of the financial report	4,000	3,800
<i>Total auditor's remuneration</i>	<u>34,500</u>	<u>32,800</u>
<b><u>Note 17 - Government grants</u></b>		
The company has recognised government grant revenue from the following levels of government and departments:		
Commonwealth		
Department of Health	250,000	327,092
	<u>250,000</u>	<u>327,092</u>
State - New South Wales		
Department of Communities and Justice	-	122,169
NSW Ministry of Health	165,600	159,600
City of Parramatta	3,943	-
	<u>169,543</u>	<u>281,769</u>
State - Queensland		
Department of Health	9,500	-
	<u>9,500</u>	<u>-</u>
State - Western Australia		
Department of Communities	20,000	-
	<u>20,000</u>	<u>-</u>
<i>Total government grants</i>	<u>449,043</u>	<u>608,861</u>

**Note 18 - Related party transactions*****Directors' remuneration***

Non Executive Directors were not entitled to and did not receive any benefits during the year. The Directors act in an honorary capacity to Epilepsy Action Australia. There were no loans in existence during the year or at balance date that were made, guaranteed or secured by the company to the Directors, their partners, relatives or entities under their control or significant influence.

**Note 19 - Economic dependency**

The company is not economically dependent on any one single supplier or client. The company is substantially dependent on the ongoing support of benefactors and donors, as well as securing government funding to underwrite various programs and activities.

**Note 20 - Limitation of members' liability**

The company is incorporated as a company limited by guarantee, and in accordance with the constitution the liability of members in the event of the company being wound up would not exceed \$10 per member. At 30 June 2025 the number of members of this company was 46 (2024: 67).

**EPILEPSY ACTION AUSTRALIA****NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025****Note 21 - Events occurring after balance date**

No significant events have occurred after balance date.

**Note 22 - Charitable fundraising activities*****Details of aggregate gross income and total expenses of fundraising appeals***

The Charitable Fundraising Act 1991 and supporting Charitable Regulations prescribe the manner in which fundraising appeals are conducted, controlled and reported in NSW.

Donations and bequests are included as income only when received at the company's administration offices or deposited to the company's bank accounts. Unsolicited donations, members donations and bequests are treated as gifts. Costs of fundraising include all direct fundraising costs and where appropriate also include an allocation of other operating expenses.

<b>Activity</b>	<b>Proceeds</b>	<b>Cost</b>	<b>Surplus</b>	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>%</b>	<b>%</b>
Mail appeals	296,967	125,719	171,248	42%	51%
Regular giving	358,339	14,444	343,895	4%	4%
Fundraising, gifts and gala events	794,943	180,899	614,044	23%	34%
	<u>1,450,249</u>	<u>321,062</u>	<u>1,129,187</u>	<u>22%</u>	<u>31%</u>

**EPILEPSY ACTION AUSTRALIA**  
**ABN 61 000 533 791**

**FINANCIAL REPORT - 30 JUNE 2025**

**DIRECTORS' DECLARATION**

The Directors of the Epilepsy Action Australia declare that:

1. The financial statements, which comprises the statement of financial position as at 30 June 2025, and the statement of profit or loss and other comprehensive income, statement of changes in funds and statement of cash flows for the year ended on that date, and notes to the financial statements, including material accounting policy information are in accordance with the *Australian Charities and Not-for-profits Commission Act 2012* and:
  - (a) comply with *Australian Accounting Standards - Simplified Disclosures* (including Australian Accounting Interpretations) and the *Australian Charities and Not-for-profits Commission Regulations 2022*; and
  - (b) give a true and fair view of the financial position of the company as at 30 June 2025 and of its performance for the year ended on that date.
2. In the opinion of the Directors, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.



Erica Siu-Gregan  
Chair

Sydney, 25 August 2025

**EPILEPSY ACTION AUSTRALIA**  
**ABN 61 000 533 791**

**FINANCIAL REPORT - 30 JUNE 2025**

**DIRECTORS' DECLARATION**  
**UNDER THE CHARITABLE FUNDRAISING ACT 1991**

In the opinion of the Directors of Epilepsy Action Australia:

- (i) The financial statements and notes thereto give a true and fair view of all income and expenditure with respect to fundraising appeals conducted by the company for the year ended 30 June 2025;
- (ii) The statement of financial position as at 30 June 2025 gives a true and fair view of the state of affairs of the company with respect to fundraising appeals conducted by the company;
- (iii) The provisions of the *Charitable Fundraising Act 1991*, the regulations under that Act, and the conditions attached to the authority to fundraise have been complied with by the company; and
- (iv) The internal controls exercised by the company are appropriate and effective in accounting for all income received and applied by the company from any of its fundraising appeals.

This declaration is made in accordance with a resolution of the Board of Directors.



Erica Siu-Gregan  
Chair

Sydney, 25 August 2025

**EPILEPSY ACTION AUSTRALIA**  
**ABN 61 000 533 791**

**FINANCIAL REPORT - 30 JUNE 2025**

**INDEPENDENT AUDITOR'S REPORT**  
**TO THE DIRECTORS OF EPILEPSY ACTION AUSTRALIA**

***Opinion***

We have audited the financial report of Epilepsy Action Australia which comprises the statement of financial position as at 30 June 2025, the statement of profit or loss and other comprehensive income, the statement of changes in funds and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information and the Directors' Declaration.

In our opinion, the accompanying financial report of Epilepsy Action Australia is in accordance with the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- a) giving a true and fair view of the company's financial position as at 30 June 2025 and of its financial performance for the year then ended; and
- b) complying with *Australian Accounting Standards - Simplified Disclosures* and the *Australian Charities and Not-for-profits Commission Regulations 2022*.

***Basis for Opinion***

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibility for the Audit of the Financial Report* section of our report. We are independent of the company in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* and the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Australian Charities and Not-for-profits Commission Act 2012*, which has been given to the Directors of the company, would be in the same terms if given to the Directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

***Directors' Responsibility for the Financial Report***

The Directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with *Australian Accounting Standards - Simplified Disclosures* and the *Australian Charities and Not-for-profits Commission Act 2012* and for such internal control as the Directors determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

The Directors are responsible for overseeing the company's financial reporting process.

**EPILEPSY ACTION AUSTRALIA**  
**ABN 61 000 533 791**

**FINANCIAL REPORT - 30 JUNE 2025**

**INDEPENDENT AUDITOR'S REPORT**  
**TO THE DIRECTORS OF EPILEPSY ACTION AUSTRALIA**

***Auditor's Responsibilities for the Audit of the Financial Report***

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at *The Auditing and Assurance Standards Board* and the website address is <http://www.auasb.gov.au/Home.aspx>

We communicate with the Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

***Report on the requirements of the New South Wales Charitable Fundraising Act 1991 and the New South Wales Charitable Fundraising Regulations 2021***

We have audited the financial report as required by Section 24 of the New South Wales *Charitable Fundraising Act 1991*. Our procedures included obtaining an understanding of the internal control structure for fundraising appeal activities and examination, on a test basis, of evidence supporting compliance with the accounting and associated record keeping requirements for fundraising appeal activities pursuant to the New South Wales *Charitable Fundraising Act 1991* and the New South Wales *Charitable Fundraising Regulations 2021*.

Because of the inherent limitations of any assurance engagement, it is possible that fraud, error or non-compliance may occur and not be detected. An audit is not designed to detect all instances of non-compliance with the requirements described in the above-mentioned Act and Regulations as an audit is not performed continuously throughout the period and the audit procedures performed in respect of compliance with these requirements are undertaken on a test basis. The audit opinion expressed in this report has been formed on the above basis.

**EPILEPSY ACTION AUSTRALIA**  
**ABN 61 000 533 791**

**FINANCIAL REPORT - 30 JUNE 2025**

**INDEPENDENT AUDITOR'S REPORT**  
**TO THE DIRECTORS OF EPILEPSY ACTION AUSTRALIA**

***Opinion***

In our opinion:

- a) The financial report of the company has been properly drawn up and associated records have been properly kept during the financial year ended 30 June 2025, in all material respects, in accordance with:
  - i. Sections 20(1), 22(1-2), 24(1) of the New South Wales *Charitable Fundraising Act 1991*; and
  - ii. Section 17 of the New South Wales *Charitable Fundraising Regulations 2021*.
- b) The money received as a result of fundraising appeals conducted by the company during the financial year ended 30 June 2024 has been properly accounted for and applied, in all material respects, in accordance with the above-mentioned Act and Regulations.



**StewartBrown**  
Chartered Accountants



**David Gallery**  
Partner

25 August 2025